Lung Cancer, Tuberculin Reactivity, and Isoniazid

Mm, Alhashimi; Ml, Citron; Be, Fossieck; Sm, Steinberg; Johnston-Early, Anita; Sh, Krasnow; Mh, Cohen

doi:10.1097/00007611-198803000-00013

Cited by 4 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Table 1 summarises the characteristics of the included studies [24][25][26][27][28][29][30][31][32][33][34][35][36].…”

Section: Resultsmentioning

confidence: 99%

“…Wu (2011) Seo (2016) Chen (2011) Liu (2015) Kim (2008) Huang (2011) Kim (2014) Fang (2015) Choi (2015) Jung (2016) Alhashimi ( Only one study provided a prevalence estimate of LTBI, based on the TST/IGRA in the study cohort (89/ 257, 35%), and stated that five patients received LTBI treatment [34]. These patients were, however, excluded from the analysis.…”

Section: Studymentioning

confidence: 99%

“…No other study indicated whether participants received treatment for LTBI. Six studies, four of which evaluated TB exclusively in gastric cancer, included information on the history of TB treatment and/or radiological evidence of previously healed TB [28-31, 33, 34], with a prevalence of previous TB on chest radiographs ranging from 7% [34] to 17% [28] in the study population. There was a paucity of available information on HIV status.…”

Section: Studymentioning

confidence: 99%

See 2 more Smart Citations

Risk of tuberculosis in patients with solid cancers and haematological malignancies: a systematic review and meta-analysis

et al. 2017

View full text Add to dashboard Cite

There is uncertainty regarding whether patients with cancer should be screened for latent tuberculosis infection (LTBI). We performed a systematic review and meta-analysis to estimate the relative incidence of tuberculosis (TB) in cancer.We searched MEDLINE and Embase for studies published before December 21, 2016. We included studies that evaluated the incidence of TB in patients with solid cancers and haematological malignancies relative to a reference group (study control or general population). A pooled estimate of the incidence rate ratio (IRR) was obtained using standard meta-analysis methods.The search strategy identified 13 unique studies including 921 464 patients with cancer. The IRR of TB for adult patients with cancer was 2.61 (95% CI 2.12-3.22; I 2 =91%). In haematological cancers, the IRR was 3.53 (95% CI 1.63-7.64; I 2 =96%); and in solid cancers in adults, it was 2.25 (95% CI 1.96-2.58; I 2 =91%). The highest IRR was found in children with haematological malignancies or solid cancers (IRR 16.82,; I 2 =79%). Considering the limited duration of maximum immunosuppression in cancer and reduced cumulative lifetime risk of TB because of reduced life expectancy, children, but not adults, appear to be at a sufficient level of risk to warrant systematic screening for LTBI.

show abstract

“…Table 1 summarises the characteristics of the included studies [24][25][26][27][28][29][30][31][32][33][34][35][36].…”

Section: Resultsmentioning

confidence: 99%

Section: Studymentioning

confidence: 99%

Section: Studymentioning

confidence: 99%

See 1 more Smart Citation

Risk of tuberculosis in patients with solid cancers and haematological malignancies: a systematic review and meta-analysis

et al. 2017

View full text Add to dashboard Cite

show abstract

“… 62 This is higher than the incidence of Mtb reactivation in lung cancer reported in the 1980s, when generally higher doses of cytotoxic chemotherapy were used. 63 Also, a single-centre cohort in South Korea identified three cases of Mtb and calculated an incidence rate of 394.4 per 100 000 person years, higher than the rate in the South Korean population in 2018 and previous studies that included patients with lung cancer. 64 Finally, a single-centre cohort in Singapore showed that 4/191 (2.09%) of patients developed Mtb reactivation following PD-1/PD-L1 blockade.…”

Section: Introductionmentioning

confidence: 99%

Infections due to dysregulated immunity: an emerging complication of cancer immunotherapy

Morelli

Fujita

Redelman-Sidi

et al. 2021

Thorax

View full text Add to dashboard Cite

Immune checkpoint inhibitors (ICIs) have revolutionised cancer treatment. However, immune-related adverse events (irAEs) are a common side effect which can mimic infection. Additionally, treatment of irAEs with corticosteroids and other immunosuppressant agents can lead to opportunistic infection, which we have classed as immunotherapy infections due to immunosuppression. However, emerging reports demonstrate that some infections can be precipitated by ICIs in the absence of immunosuppressive treatment, in contrast to the majority of reported cases. These infections are characterised by a dysregulated inflammatory immune response, and so we propose they are described as immunotherapy infections due to dysregulated immunity. This review summarises the rapidly emerging evidence of these phenomena and proposes a new framework for considering infection in the context of cancer immunotherapy.

show abstract

Risk of Active Tuberculosis in Patients With Cancer: A Systematic Review and Metaanalysis

Cheng

Chakra

Yansouni

et al. 2016

Clinical Infectious Diseases

View full text Add to dashboard Cite

show abstract

Lung Cancer, Tuberculin Reactivity, and Isoniazid

Cited by 4 publications

References 0 publications

Risk of tuberculosis in patients with solid cancers and haematological malignancies: a systematic review and meta-analysis

Risk of tuberculosis in patients with solid cancers and haematological malignancies: a systematic review and meta-analysis

Infections due to dysregulated immunity: an emerging complication of cancer immunotherapy

Risk of Active Tuberculosis in Patients With Cancer: A Systematic Review and Metaanalysis

Contact Info

Product

Resources

About